[HTML][HTML] Senescence and cancer—role and therapeutic opportunities
Cellular senescence is a state of stable, terminal cell cycle arrest associated with various
macromolecular changes and a hypersecretory, pro-inflammatory phenotype. Entry of cells …
macromolecular changes and a hypersecretory, pro-inflammatory phenotype. Entry of cells …
[HTML][HTML] Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
ME Bahar, HJ Kim, DR Kim - Signal transduction and targeted therapy, 2023 - nature.com
Metastatic dissemination of solid tumors, a leading cause of cancer-related mortality,
underscores the urgent need for enhanced insights into the molecular and cellular …
underscores the urgent need for enhanced insights into the molecular and cellular …
E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers
HB Park, KH Baek - Biochimica et Biophysica Acta (BBA)-Reviews on …, 2022 - Elsevier
The mitogen-activated protein kinase (MAPK) signaling pathway is the primary regulatory
module of various cellular processes such as cell proliferation, differentiation, and stress …
module of various cellular processes such as cell proliferation, differentiation, and stress …
[HTML][HTML] Ferroptosis and EMT: key targets for combating cancer progression and therapy resistance
Y Ren, X Mao, H Xu, Q Dang, S Weng, Y Zhang… - Cellular and Molecular …, 2023 - Springer
Iron-dependent lipid peroxidation causes ferroptosis, a form of regulated cell death. Crucial
steps in the formation of ferroptosis include the accumulation of ferrous ions (Fe2+) and lipid …
steps in the formation of ferroptosis include the accumulation of ferrous ions (Fe2+) and lipid …
[HTML][HTML] RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics
Accumulating research suggests that the tumor immune microenvironment (TIME) plays an
essential role in regulation of tumor growth and metastasis. The cellular and molecular …
essential role in regulation of tumor growth and metastasis. The cellular and molecular …
[HTML][HTML] Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen
KM Wright, SR DiNapoli, MS Miller… - Nature …, 2023 - nature.com
Specificity remains a major challenge to current therapeutic strategies for cancer. Mutation
associated neoantigens (MANAs) are products of genetic alterations, making them highly …
associated neoantigens (MANAs) are products of genetic alterations, making them highly …
[HTML][HTML] Structural insight into the bulge-containing KRAS oncogene promoter G-quadruplex bound to berberine and coptisine
KB Wang, Y Liu, J Li, C Xiao, Y Wang, W Gu… - Nature …, 2022 - nature.com
KRAS is one of the most highly mutated oncoproteins, which is overexpressed in various
human cancers and implicated in poor survival. The G-quadruplex formed in KRAS …
human cancers and implicated in poor survival. The G-quadruplex formed in KRAS …
[HTML][HTML] Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
G Yin, J Huang, J Petela, H Jiang, Y Zhang… - Signal transduction and …, 2023 - nature.com
Abstract Small GTPases including Ras, Rho, Rab, Arf, and Ran are omnipresent molecular
switches in regulating key cellular functions. Their dysregulation is a therapeutic target for …
switches in regulating key cellular functions. Their dysregulation is a therapeutic target for …
CUL4B functions as a tumor suppressor in KRAS-driven lung tumors by inhibiting the recruitment of myeloid-derived suppressor cells
X Liu, F Tian, J Cui, L Gong, L Xiang, B Fan, S Liu… - Oncogene, 2023 - nature.com
Lung cancer is the leading cause of cancer-related death worldwide. KRAS mutations are
the most common oncogenic alterations found in lung cancer. Unfortunately, treating KRAS …
the most common oncogenic alterations found in lung cancer. Unfortunately, treating KRAS …
[HTML][HTML] Cancer therapy guided by mutation tests: current status and perspectives
SN Aleksakhina, EN Imyanitov - International journal of molecular …, 2021 - mdpi.com
The administration of many cancer drugs is tailored to genetic tests. Some genomic events,
eg, alterations of EGFR or BRAF oncogenes, result in the conformational change of the …
eg, alterations of EGFR or BRAF oncogenes, result in the conformational change of the …